Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-05-13 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司將召開線上法人說明會
Investor Presentation Classification · 95% confidence The document is a short announcement (722 characters) about the scheduling of an online investor conference call (法人說明會) by the company 美時 (1795). It specifies the date, time, and format of the event, including links to webcast and telephone conference. There is no detailed financial data or report content included, only an invitation and description of the event. This matches the definition of an Investor Presentation (IP) as it focuses on financial and operational information shared with investors in a presentation format. It is not a transcript or full report, nor is it a regulatory filing or announcement of a report publication. Therefore, the classification is Investor Presentation (IP).
2022-05-13 Chinese
公告本公司董事會決議通過私募普通股補辦公開發行
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company (美時化學製藥股份有限公司) regarding a board resolution to convert previously privately placed common shares into a public offering. It mentions the date of the board decision and references regulatory compliance with securities laws. The content is about a capital/financing activity (private placement shares becoming publicly offered). The document length is only 654 characters, indicating it is a brief announcement rather than a detailed report. There is no financial data or detailed financial statements, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention a report being published or attached. The subject matter fits best under Capital/Financing Update (CAP) as it concerns share issuance and capital structure changes.
2022-05-13 Chinese
公告本公司董事會決議通過111年第一季財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1795 美時) reporting the board's approval of the first quarter financial report for the period 111/01/01 to 111/03/31 (Taiwan calendar year). It includes summarized financial data such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity. The document length is short (912 characters) and it is an announcement of the board resolution approving the quarterly financial report rather than the full detailed report itself. This fits the definition of an Interim / Quarterly Report (IR) as it contains substantive financial data for a period shorter than a full fiscal year. Therefore, the classification is IR with high confidence. Q1 2022
2022-05-13 Chinese
111年04月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tabular data listing shareholdings and changes in shareholdings by insiders, including directors, managers, and other key personnel. It includes specific share counts, increases, decreases, and trust holdings. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or regulatory announcement. The document matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data, not just an announcement or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-05-12 Chinese
111年04月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 美時化學製藥股份有限公司, including directors, independent directors, managers, and major shareholders. It lists the number of shares held, pledged shares, and related ratios. There is no indication of financial statements, earnings data, or management discussion. The document is focused on insider shareholdings and their changes, which aligns with reporting of personal share transactions or holdings by company directors and executives. The document length is 3585 characters, which is relatively short but contains detailed insider shareholding data. This matches the definition of Director's Dealing (DIRS) filings, which report personal share transactions by company directors and executives. Therefore, the appropriate classification is DIRS.
2022-05-12 Chinese
111年4月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 美時, providing information about fund loans and endorsement guarantees for the current and previous month, including cumulative balances and limits. It contains no detailed financial statements, management discussion, or regulatory certifications. The document length is very short (619 characters), and it primarily reports specific financial data related to guarantees and loans without broader context or analysis. This type of disclosure fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-05-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.